

Dyfrig A Hughes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1555785/dyfrig-a-hughes-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203
papers

6,750
citations

42
h-index

76
g-index

245
ext. papers

8,109
ext. citations

4.8
avg, IF

6.11
L-index

#	Paper	IF	Citations
203	Supporting People With Type 2 Diabetes in the Effective Use of Their Medicine Through Mobile Health Technology Integrated With Clinical Care to Reduce Cardiovascular Risk: Protocol for an Effectiveness and Cost-effectiveness Randomized Controlled Trial.. <i>JMIR Research Protocols</i> , 2022 , 11, e32913	2	
202	Health utilities and costs for neuromyelitis optica spectrum disorder.. <i>Orphanet Journal of Rare Diseases</i> , 2022 , 17, 159	4.2	2
201	Mechanistically informed non-invasive peripheral nerve stimulation for peripheral neuropathic pain: a randomised double-blind sham-controlled trial. <i>Journal of Translational Medicine</i> , 2021 , 19, 458	8.5	0
200	Liothyronine for hypothyroidism: a candidate for disinvestment or in need of further research? A value of information analysis. <i>BMJ Open</i> , 2021 , 11, e051702	3	0
199	Is there a role for natural desiccated thyroid in the treatment of levothyroxine unresponsive hypothyroidism? Results from a consecutive case series. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14967	2.9	1
198	Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 49-63	6.1	3
197	Microdiscectomy compared with transforaminal epidural steroid injection for persistent radicular pain caused by prolapsed intervertebral disc: the NERVES RCT. <i>Health Technology Assessment</i> , 2021 , 25, 1-86	4.4	0
196	Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey. <i>Value in Health</i> , 2021 , 24, 539-547	3.3	10
195	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 1363-1374	4.0	29
194	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 1375-1386	4.0	37
193	The Role of Prevention in Reducing the Economic Impact of ME/CFS in Europe: A Report from the Socioeconomics Working Group of the European Network on ME/CFS (EUROMENE). <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	1
192	Cost-effectiveness of home versus hospital management of children at onset of type 1 diabetes: the DECIDE randomised controlled trial. <i>BMJ Open</i> , 2021 , 11, e043523	3	1
191	Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controlled trial and economic evaluation. <i>Lancet Rheumatology, The</i> , 2021 , 3, e347-e356	14.2	6
190	Pharmacogenomics spotlight commentary: From the United Kingdom to global populations. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
189	A systematic review of economic evaluations of advanced therapy medicinal products. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2428-2443	3.8	14
188	Managing access to advanced therapy medicinal products: Challenges for NHS Wales. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2444-2449	3.8	3
187	What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristics. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 251-260	2.8	5

186	Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions. <i>Pharmacoeconomics</i> , 2021 , 39, 25-61	4.4	1
185	Acceptability of generic versus innovator oral medicines: not only a matter of taste. <i>Drug Discovery Today</i> , 2021 , 26, 329-343	8.8	5
184	Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 75-83	4.5	1
183	TEOS: A framework for constructing operational definitions of medication adherence based on Timelines-Events-Objectives-Sources. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2521-2533	3.8	2
182	Early impact of COVID-19 social distancing measures on reported sexual behaviour of HIV pre-exposure prophylaxis users in Wales. <i>Sexually Transmitted Infections</i> , 2021 , 97, 85-87	2.8	13
181	Utilising benefit-risk assessments within clinical trials-a protocol for the BRAINS project. <i>Trials</i> , 2021 , 22, 68	2.8	
180	EstablishING the best STEp-up treatments for children with uncontrolled asthma despite INhaled corticosteroids (EINSTEIN): protocol for a systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data (IPD). <i>BMJ Open</i> , 2021 , 11, e040528	3	
179	Perceptions of European ME/CFS Experts Concerning Knowledge and Understanding of ME/CFS among Primary Care Physicians in Europe: A Report from the European ME/CFS Research Network (EUROMENE). <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	5
178	Using routinely recorded data in a UK RCT: a comparison to standard prospective data collection methods. <i>Trials</i> , 2021 , 22, 429	2.8	0
177	Plasma Methylmalonic Acid Concentration in Folic Acid-Supplemented Depressed Patients with Low or Marginal Vitamin B-12: A Randomized Trial. <i>Journal of Nutrition</i> , 2021 , 151, 3738-3745	4.1	
176	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.. <i>Health Technology Assessment</i> , 2021 , 25, 1-134	4.4	2
175	Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam. <i>British Journal of Pharmacology</i> , 2020 , 177, 4975-4989	8.6	10
174	Seizure first aid training for people with epilepsy attending emergency departments and their significant others: the SAFE intervention and feasibility RCT. <i>Health Services and Delivery Research</i> , 2020 , 8, 1-190	1.5	2
173	Silver-impregnated, antibiotic-impregnated or non-impregnated ventriculoperitoneal shunts to prevent shunt infection: the BASICS three-arm RCT. <i>Health Technology Assessment</i> , 2020 , 24, 1-114	4.4	7
172	Carer administration of as-needed subcutaneous medication for breakthrough symptoms in people dying at home: the CARIAD feasibility RCT. <i>Health Technology Assessment</i> , 2020 , 24, 1-150	4.4	3
171	A Literature Review of GP Knowledge and Understanding of ME/CFS: A Report from the Socioeconomic Working Group of the European Network on ME/CFS (EUROMENE). <i>Medicina (Lithuania)</i> , 2020 , 57,	3.1	10
170	The New and Non-Transparent Cancer Drugs Fund. <i>Pharmacoeconomics</i> , 2020 , 38, 1-4	4.4	9
169	Management of Patients Symptomatically Unresponsive to Levothyroxine: Natural Desiccated Thyroid Extract or the Combination of Levothyroxine and Liothyronine? A Research Priority. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020 , 128, 596-598	2.3	1

168	Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II). <i>BMJ Open</i> , 2020 , 10, e040635	3	4
167	Impact of Relaxing Covid-19 Social Distancing Measures on Rural North Wales: A Simulation Analysis. <i>Frontiers in Public Health</i> , 2020 , 8, 562473	6	1
166	Seizure First Aid Training For people with Epilepsy (SAFE) frequently attending emergency departments and their significant others: results of a UK multi-centre randomised controlled pilot trial. <i>BMJ Open</i> , 2020 , 10, e035516	3	1
165	The Development of a Consistent Europe-Wide Approach to Investigating the Economic Impact of Myalgic Encephalomyelitis (ME/CFS): A Report from the European Network on ME/CFS (EUROMENE). <i>Healthcare (Switzerland)</i> , 2020 , 8,	3.4	22
164	Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Methodological Papers. <i>Medical Decision Making</i> , 2019 , 39, 910-925	2.5	3
163	Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. <i>Journal of Personalized Medicine</i> , 2019 , 9,	3.6	1
162	Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation. <i>Lancet, The</i> , 2019 , 394, 1530-1539	4.0	58
161	Challenges for Economic Evaluation of Health Care Strategies to Contain Antimicrobial Resistance. <i>Antibiotics</i> , 2019 , 8,	4.9	5
160	What really matters? A mixed methods study of treatment preferences and priorities among people with epilepsy in the UK. <i>Epilepsy and Behavior</i> , 2019 , 95, 181-191	3.2	5
159	Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 652-660	6.1	3
158	Core Health Outcomes in Childhood Epilepsy (CHOICE): Development of a core outcome set using systematic review methods and a Delphi survey consensus. <i>Epilepsia</i> , 2019 , 60, 857-871	6.4	16
157	Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 978-996	6.1	8
156	CARer-ADministration of as-needed subcutaneous medication for breakthrough symptoms in homebased dying patients (CARIAD): study protocol for a UK-based open randomised pilot trial. <i>Trials</i> , 2019 , 20, 105	2.8	4
155	Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation. <i>BMJ, The</i> , 2019 , 365, l1226	5.9	31
154	Health Utilities and Costs for Motor Neurone Disease. <i>Value in Health</i> , 2019 , 22, 1257-1265	3.3	8
153	Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. <i>Pharmacoeconomics</i> , 2019 , 37, 1509-1523	4.4	4
152	Medicines Shortages in the United Kingdom. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 712	6.1	2
151	A Fully Integrated Real-Time Detection, Diagnosis, and Control of Community Diarrheal Disease Clusters and Outbreaks (the INTEGRATE Project): Protocol for an Enhanced Surveillance System. <i>JMIR Research Protocols</i> , 2019 , 8, e13941	2	3

150	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. <i>Health Technology Assessment</i> , 2019 , 23, 1-140	4.4	10
149	Reply. <i>Ophthalmology</i> , 2019 , 126, e24-e25	7.3	
148	Improving medication adherence research reporting: ESPACOMP Medication Adherence Reporting Guideline (EMERGE). <i>European Journal of Cardiovascular Nursing</i> , 2019 , 18, 258-259	3.3	6
147	Developing patient-centred, feasible alternative care for adult emergency department users with epilepsy: protocol for the mixed-methods observational CollaborateProject. <i>BMJ Open</i> , 2019 , 9, e031696	3.6	3
146	Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMIT-D Feasibility): a randomised feasibility trial protocol. <i>BMJ Open</i> , 2019 , 9, e033504	3	5
145	Community views on factors affecting medicines resource allocation: cross-sectional survey of 3080 adults in Australia. <i>Australian Health Review</i> , 2019 , 43, 254-260	1.8	5
144	Patient-Focused Drug Development Methods for Benefit-Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 672-683	6.1	13
143	Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. <i>Ophthalmology</i> , 2019 , 126, 415-424	7.3	14
142	Cost-Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation Framework. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1429-1438	6.1	12
141	Rare disease prevention and treatment: the need for a level playing field. <i>Pharmacogenomics</i> , 2018 , 19, 243-247	2.6	3
140	Economics of Pharmacogenetic-Guided Treatments: Underwhelming or Overstated?. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 749-751	6.1	9
139	New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. <i>Pharmacoeconomics</i> , 2018 , 36, 613-624	4.4	6
138	Impact of the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales. <i>Health Economics (United Kingdom)</i> , 2018 , 27, 236-243	2.4	1
137	Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 142-152	3.8	10
136	Core Items for a Standardized Resource Use Measure: Expert Delphi Consensus Survey. <i>Value in Health</i> , 2018 , 21, 640-649	3.3	28
135	Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease. <i>Value in Health</i> , 2018 , 21, 1322-1329	3.3	6
134	ESPACOMP Medication Adherence Reporting Guideline (EMERGE). <i>Annals of Internal Medicine</i> , 2018 , 169, 30-35	8	138
133	Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model. <i>Value in Health</i> , 2018 , 21, 1373-1381	3.3	8

132	Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC). <i>Trials</i> , 2018 , 19, 408	2.8	1
131	Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods. <i>Value in Health</i> , 2018 , 21, 538-546	3.3	16
130	Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. <i>Journal of Neurosurgery</i> , 2018 , 129, 1104-1105	3.2	1
129	Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT. <i>Health Technology Assessment</i> , 2018 , 22, 1-112	4.4	13
128	Health Technology Assessment (HTA) for Smaller Countries: The role of the health economist. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, SY11-3	0	
127	Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care. <i>Antibiotics</i> , 2018 , 7,	4.9	14
126	Nerve root block versus surgery (NERVES) for the treatment of radicular pain secondary to a prolapsed intervertebral disc herniation: study protocol for a multi-centre randomised controlled trial. <i>Trials</i> , 2018 , 19, 475	2.8	4
125	Innovation at the Intersection of Clinical Trials and Real-World Data Science to Advance Patient Care. <i>Clinical and Translational Science</i> , 2018 , 11, 450-460	4.9	22
124	Affordable orphan drugs: a role for not-for-profit organizations. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1595-1601	3.8	21
123	Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2017 , 376, 1637-1646	59.2	218
122	Economic Studies in Motor Neurone Disease: A Systematic Methodological Review. <i>Pharmacoeconomics</i> , 2017 , 35, 397-413	4.4	5
121	Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. <i>Rheumatology</i> , 2017 , 56, 1729-1739	3.9	35
120	Renal transplant patients preference for the supply and delivery of immunosuppressants in Wales: a discrete choice experiment. <i>BMC Nephrology</i> , 2017 , 18, 305	2.7	1
119	Core Health Outcomes In Childhood Epilepsy (CHOICE): protocol for the selection of a core outcome set. <i>Trials</i> , 2017 , 18, 572	2.8	9
118	Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review. <i>Thorax</i> , 2017 ,	7.3	3
117	Cost-effectiveness of HLA-B*15:02 screening in Malaysia. <i>British Journal of Dermatology</i> , 2017 , 177, 904-905	4.05	4
116	Comparing Generic and Condition-Specific Preference-Based Measures in Epilepsy: EQ-5D-3L and NEWQOL-6D. <i>Value in Health</i> , 2017 , 20, 687-693	3.3	19
115	Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial. <i>Frontiers in Pharmacology</i> , 2017 , 8, 644	5.6	3

114	Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia. <i>PLoS ONE</i> , 2017 , 12, e0172971	3.7	16
113	Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATIC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. <i>Health Technology Assessment</i> , 2017 , 21, 1-180	4.4	19
112	Drug utilization research and pharmacoeconomics 2016 , 425-432		
111	A randomised, patient-assessor blinded, sham-controlled trial of external non-invasive peripheral nerve stimulation for chronic neuropathic pain following peripheral nerve injury (EN-PENS trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2016 , 17, 574	2.8	3
110	Multiple imputation of multiple multi-item scales when a full imputation model is infeasible. <i>BMC Research Notes</i> , 2016 , 9, 45	2.3	33
109	Opportunity costs and local health service spending decisions: a qualitative study from Wales. <i>BMC Health Services Research</i> , 2016 , 16, 103	2.9	17
108	A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. <i>Pharmacoeconomics</i> , 2016 , 34, 771-93	4.4	83
107	A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration. <i>Patient</i> , 2016 , 9, 281-92	3.7	16
106	Impregnated central venous catheters for prevention of bloodstream infection in children (the CATCH trial): a randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1732-42	4.0	73
105	Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches. <i>Pharmacoeconomics</i> , 2016 , 34, 447-61	4.4	26
104	Generalisability and Cost-Impact of Antibiotic-Impregnated Central Venous Catheters for Reducing Risk of Bloodstream Infection in Paediatric Intensive Care Units in England. <i>PLoS ONE</i> , 2016 , 11, e0151348	2.7	18
103	CATHeter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children. <i>Health Technology Assessment</i> , 2016 , 20, vii-xxviii, 1-219	4.4	16
102	Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study. <i>PLoS ONE</i> , 2016 , 11, e0164681	3.7	28
101	What influences persistence with medicines? A multinational discrete choice experiment of 2549 patients. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 522-31	3.8	8
100	Prof. John Urquhart. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 573	3.8	1
99	NICE recommendations: why no disinvestment recommendations to offset investment decisions?. <i>BMJ, The</i> , 2015 , 350, h2656	5.9	
98	Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria. <i>Wiener Klinische Wochenschrift</i> , 2015 , 127, 379-84	2.3	6
97	Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey. <i>Value in Health</i> , 2015 , 18, 206-16	3.3	47

96	How many Epley manoeuvres are required to treat benign paroxysmal positional vertigo?. <i>Journal of Laryngology and Otology</i> , 2015 , 129, 421-4	1.8	14
95	Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. <i>Epilepsia</i> , 2015 , 56, 556-63	6.4	46
94	Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. <i>Value in Health</i> , 2015 , 18, 906-14	3.3	169
93	The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. <i>Trials</i> , 2015 , 16, 519	2.8	117
92	Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients and physicians' preferences for testing and service delivery. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1149-59	3.8	22
91	Taxonomy for methods of resource use measurement. <i>Health Economics (United Kingdom)</i> , 2015 , 24, 372-8	2.4	16
90	Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence. <i>Epilepsy and Behavior</i> , 2015 , 45, 180-6	3.2	11
89	Study protocol for a randomised controlled trial of insulin delivery by continuous subcutaneous infusion compared to multiple daily injections. <i>Trials</i> , 2015 , 16, 163	2.8	7
88	Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015 , 370,	5.8	12
87	Evaluation of a consultant audit and feedback programme to improve the quality of antimicrobial prescribing in acute medical admissions. <i>International Journal of Pharmacy Practice</i> , 2015 , 23, 333-9	1.7	7
86	Does electronic monitoring influence adherence to medication? Randomized controlled trial of measurement reactivity. <i>Annals of Behavioral Medicine</i> , 2014 , 48, 293-9	4.5	46
85	Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 199-207	6.1	51
84	Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population. <i>Epilepsy and Behavior</i> , 2014 , 36, 12-7	3.2	12
83	Predicting adherence to medications using health psychology theories: a systematic review of 20 years of empirical research. <i>Value in Health</i> , 2014 , 17, 863-76	3.3	100
82	A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). <i>Trials</i> , 2014 , 15, 14	2.8	64
81	The British antibiotic and silver-impregnated catheters for ventriculoperitoneal shunts multi-centre randomised controlled trial (the BASICS trial): study protocol. <i>Trials</i> , 2014 , 15, 4	2.8	39
80	Folate Augmentation of Treatment--Evaluation for Depression (FoLATED): randomised trial and economic evaluation. <i>Health Technology Assessment</i> , 2014 , 18, vii-viii, 1-159	4.4	20
79	Resource-use measurement based on patient recall: issues and challenges for economic evaluation. <i>Applied Health Economics and Health Policy</i> , 2013 , 11, 155-61	3.4	59

78	Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. <i>Drugs</i> , 2013 , 73, 545-62	12.1	214
77	Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. <i>Value in Health</i> , 2013 , 16, 863-71	3.3	102
76	Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity. <i>Pharmacoeconomics</i> , 2013 , 31, 345-55	4.4	29
75	Pharmacogenetic tests: the need for a level playing field. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 3-4	64.1	30
74	Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 269-76	6.1	18
73	Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. <i>Health Economics (United Kingdom)</i> , 2013 , 22, 948-64	2.4	131
72	Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. <i>Pharmacogenomics</i> , 2013 , 14, 151-63	2.6	12
71	New advice on switching antiepileptic drugs might be a false economy. <i>BMJ, The</i> , 2013 , 347, f7471	5.9	1
70	A new taxonomy for describing and defining adherence to medications. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 691-705	3.8	910
69	Pharmacoeconomics. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 968-72	3.8	8
68	The development of a QALY measure for epilepsy: NEWQOL-6D. <i>Epilepsy and Behavior</i> , 2012 , 24, 36-43	3.2	51
67	Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. <i>Pharmacogenomics</i> , 2012 , 13, 1405-17	2.6	15
66	An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes. <i>BMC Family Practice</i> , 2012 , 13, 30	2.6	41
65	A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 91, 829-37	6.1	19
64	Development of a database of instruments for resource-use measurement: purpose, feasibility, and design. <i>Value in Health</i> , 2012 , 15, 650-5	3.3	48
63	Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. <i>Value in Health</i> , 2012 , 15, 1162-71	3.3	100
62	Defining rewardable innovation in drug therapy. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 253-4	64.1	35
61	Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors. <i>Pharmacoeconomics</i> , 2012 , 30, 779-94	4.4	23

60	Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma. <i>Pharmacoeconomics</i> , 2012 , 30, 413-29	4.4	17
59	The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 66-76	3.8	57
58	Ring-fencing a budget for cancer drugs: is it fair?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2011 , 41, 224-8	0.9	4
57	HTAs and rare diseases: How to assess their cost-effectiveness. <i>Pharmaceuticals Policy and Law</i> , 2011 , 13, 161-165		2
56	Generic substitution: authorsResponse. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 968-968	3.8	78
55	Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. <i>BMJ, The</i> , 2011 , 343, d6333	5.9	117
54	Abolition of prescription copayments in Wales: an observational study on dispensing rates. <i>Value in Health</i> , 2010 , 13, 675-80	3.3	11
53	Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. <i>Value in Health</i> , 2010 , 13, 867-72	3.3	67
52	Generic and therapeutic substitutions in the UK: are they a good thing?. <i>British Journal of Clinical Pharmacology</i> , 2010 , 70, 335-41	3.8	98
51	Biosimilars: evidential standards for health technology assessment. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 257-61	6.1	13
50	062 Abolition of prescription co-payments in Wales: an observational study on dispensing rates. <i>Journal of Epidemiology and Community Health</i> , 2010 , 64, A25-A25	5.1	
49	A systematic review and empirical analysis of the relation between dose and duration of drug action. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 17-26	2.9	6
48	Abolition of prescription charges in Wales: the impact on medicines use in those who used to pay. <i>International Journal of Pharmacy Practice</i> , 2010 , 18, 332-40	1.7	7
47	Is exercise effective in promoting mental well-being in older age? A systematic review. <i>Aging and Mental Health</i> , 2010 , 14, 652-69	3.5	183
46	A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. <i>Pharmacogenomics</i> , 2010 , 11, 989-1002	2.6	19
45	NICE and new: appraising innovation. <i>BMJ, The</i> , 2010 , 340, b5493	5.9	32
44	New drugs for old: disinvestment and NICE. <i>BMJ, The</i> , 2010 , 340, c572	5.9	27
43	The problem of orphan drugs. <i>BMJ, The</i> , 2010 , 341, c6456	5.9	11

42	Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees. <i>Clinical Medicine</i> , 2009 , 9, 490-2	1.9	4
41	A framework for planning and critiquing medication compliance and persistence research using prospective study designs. <i>Clinical Therapeutics</i> , 2009 , 31, 421-35	3.5	28
40	Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 265-74	6.1	96
39	Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review. <i>Journal of Advanced Nursing</i> , 2009 , 65, 706-23	3.1	124
38	Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. <i>Value in Health</i> , 2009 , 12, 915-22	3.3	81
37	Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. <i>Malaria Journal</i> , 2009 , 8, 204	3.6	51
36	Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations. <i>Pharmacoeconomics</i> , 2009 , 27, 635-43	4.4	6
35	Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 800-12	1.9	49
34	Patients and healthcare professionals' views of cancer follow-up: systematic review. <i>British Journal of General Practice</i> , 2009 , 59, e248-59	1.6	92
33	Follow-up of cancer in primary care versus secondary care: systematic review. <i>British Journal of General Practice</i> , 2009 , 59, e234-47	1.6	105
32	Understanding medication compliance and persistence from an economics perspective. <i>Value in Health</i> , 2008 , 11, 600-10	3.3	45
31	Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 871-8	3.8	10
30	Medicines concordance and game theory. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 577	3.8	
29	NHS and charitable funding for children and young people with cancer in England and Wales. <i>Journal of Child Health Care</i> , 2008 , 12, 156-68	2	4
28	Non-compliance with antibiotic therapy for acute community infections: a global survey. <i>International Journal of Antimicrobial Agents</i> , 2007 , 29, 245-53	14.3	83
27	A global survey of antibiotic leftovers in the outpatient setting. <i>International Journal of Antimicrobial Agents</i> , 2007 , 30, 530-6	14.3	32
26	Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial. <i>BMC Psychiatry</i> , 2007 , 7, 65	4.2	25
25	Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 82, 123-7	6.1	29

24	Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. <i>Value in Health</i> , 2007 , 10, 498-509	3.3	72
23	Feasibility, validity and reliability of the Welsh version of the EQ-5D health status questionnaire. <i>Quality of Life Research</i> , 2007 , 16, 1419-23	3.7	6
22	Parenting programme for parents of children at risk of developing conduct disorder: cost effectiveness analysis. <i>BMJ, The</i> , 2007 , 334, 682	5.9	125
21	When drugs don't work: economic assessment of enhancing compliance with interventions supported by electronic monitoring devices. <i>Pharmacoeconomics</i> , 2007 , 25, 621-35	4.4	26
20	Beyond registration--measuring the public-health potential of new treatments for malaria in Africa. <i>Lancet Infectious Diseases, The</i> , 2006 , 6, 46-52	25.5	17
19	Orphan drugs revisited: author's response. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006 , 99, 350-351	2.7	2
18	Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 289-300	3.8	20
17	Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. <i>Pharmacoeconomics</i> , 2005 , 23, 1031-41	4.4	17
16	Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: pharmacoeconomic considerations. <i>European Journal of Cancer</i> , 2005 , 41, 1655; author reply 1656-7	7.5	
15	Trends and influences on use of antidiabetic drugs in England, 1992-2003. <i>Pharmacoepidemiology and Drug Safety</i> , 2005 , 14, 769-73	2.6	17
14	Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005 , 5, 29-38	2.2	2
13	Drugs for exceptionally rare diseases: do they deserve special status for funding?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005 , 98, 829-36	2.7	141
12	The difference between effectiveness and efficacy of antimalarial drugs in Kenya. <i>Tropical Medicine and International Health</i> , 2004 , 9, 967-74	2.3	21
11	Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. <i>Pharmacoeconomics</i> , 2004 , 22, 1047-59	4.4	20
10	Clinical pharmacology: special safety considerations in drug development and pharmacovigilance. <i>Drug Safety</i> , 2004 , 27, 535-54	5.1	20
9	Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 335-42		236
8	Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 1-8	6.1	23
7	Economic impact of poor compliance with pharmaceuticals. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2002 , 2, 327-35	2.2	8

6	The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. <i>Health Economics (United Kingdom)</i> , 2001 , 10, 601-15	2.4	116
5	Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?. <i>Pharmacoeconomics</i> , 2001 , 19, 1069-77	4.4	23
4	Accounting for noncompliance in pharmacoeconomic evaluations. <i>Pharmacoeconomics</i> , 2001 , 19, 1185-97	4.4	50
3	PMDP4: THE INFLUENCE OF NON-COMPLIANCE ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF DRUG THERAPIES. <i>Value in Health</i> , 2000 , 3, 373	3.3	2
2	Patient compliance with drug therapy for diabetic nephropathy. <i>Cmaj</i> , 2000 , 162, 1553-4	3.5	5
1	Patient charges and the utilisation of NHS prescription medicines: some estimates using a cointegration procedure. <i>Health Economics (United Kingdom)</i> , 1995 , 4, 213-20	2.4	40